| abstract |
Compounds and pharmaceutical compositions are provided to treat patients suffering from certain diseases and disorders that respond to the inhibition of KMO activity. These diseases include neurodegenerative disorders, such as Huntington's disease. Claim 1: A compound of formula (1) or any of its pharmaceutically acceptable salts or prodrug, characterized in that: R¹ is optionally substituted heteroaryl; X- is -CR²R³-; R² and R³ are independently selected from hydrogen, optionally substituted amino, hydroxyl, lower alkoxy, and optionally substituted lower alkyl; L is -C (O) O-; R⁵ is hydrogen; and R⁶ and R⁷ are independently selected from hydrogen, halogen, optionally substituted amino, hydroxy, lower alkoxy, and optionally substituted lower alkyl. |